Maïlys FERRERE

About Maïlys FERRERE

Maïlys Ferrère is a French corporate executive and board member known for her expertise in finance, capital markets, and listed-company governance. At DBV Technologies, she has served as a member of the Board of Directors since June 2016, after having first joined as a non-voting observer following the company’s IPO on Euronext Paris in March 2012. Her appointment came at an important stage in DBV’s evolution, as the company was preparing for the commercialization path of Viaskin Peanut, its epicutaneous immunotherapy platform focused on food allergies. She also holds a senior role at Bpifrance, where she has served as Director and Head of the Large Venture Investment activity since October 2013. In that capacity, she works at the intersection of growth investing, innovation financing, and support for high-potential technology companies. DBV also notes that she is affiliated with one of its significant shareholders, underscoring her familiarity with shareholder alignment, value creation, and governance discipline. Earlier in her career, Ferrère built a strong background in banking and equity capital markets. She graduated from Sciences Po Paris and began her career with the General Inspectorate of Société Générale before moving to several French banks, where she worked in equity capital markets origination. That background gave her deep experience in complex financings, IPOs, capital increases, and investor relations. Her governance track record is especially strong in life sciences and biotech. She has served on the boards of Innate Pharma, Valneva, GenSight Biologics, and Pixium Vision, and has also held board roles at Sequans Communications, Devialet, and Doctolib. DBV Technologies states that her banking experience and capital-markets knowledge make her a valuable contributor to the Board. Overall, her profile combines financial rigor, risk awareness, boardroom experience, and a deep understanding of innovative companies—skills that are particularly relevant for a listed biopharmaceutical group navigating scientific, regulatory, and financing challenges.